The global plant-based vaccines market, which amassed revenues of US$ 1.6 billion in 2024, is expected to achieve a valuation of US$ 2.9 billion by the close of 2031. Plant-based vaccines have emerged as a promising avenue for safer, more accessible, and cost-effective vaccine development.
This technology not only simplifies vaccine production but also facilitates needleless and accessible delivery methods, making it a valuable tool in global healthcare. Notably, plant-based vaccines can play a crucial role in addressing vaccine distribution challenges highlighted during recent global emergencies.
Scalability and Versatility: Plant-based systems offer the ability to produce up to 10 million vaccine doses per month, making them ideal for mass manufacturing. They can accommodate various vaccine types, including multiepitope vaccines, protein subunits, virus-like particles (VLPs), and chimeric VLPs, ensuring a wide range of vaccine options.
Affordability and Safety: Plant-based vaccine production is cost-effective, scalable, and safe. Moreover, plants enable the synthesis of recombinant proteins post glycosylation, a capability lacking in E. coli-based systems.
Development and Commercialization Gap: A knowledge gap exists between laboratory-based production and the commercialization of plant-based vaccines. This includes challenges in business planning, financing, and regulatory approval.
This product will be delivered within 1-3 business days.
Plant-Based Vaccines: A Paradigm Shift
Traditional vaccine production methods face limitations in developing vaccines for certain deadly diseases. The concept of using plants as bioreactors to produce edible vaccines has gained prominence, offering a cost-effective alternative with easy scalability. Plants like tobacco, maize, potatoes, rice, and tomatoes have served as biofactories for vaccine development.This technology not only simplifies vaccine production but also facilitates needleless and accessible delivery methods, making it a valuable tool in global healthcare. Notably, plant-based vaccines can play a crucial role in addressing vaccine distribution challenges highlighted during recent global emergencies.
Driving Factors for Plant-Based Vaccine Manufacturers:
Rapid and Cost-Effective Synthesis: Transient expression systems in plant-based vaccine manufacturing can produce target antigens within a week, making them a vital option for rapid vaccine development. This capability is particularly valuable during emergencies like the COVID-19 pandemic, allowing for the swift creation of vaccines.Scalability and Versatility: Plant-based systems offer the ability to produce up to 10 million vaccine doses per month, making them ideal for mass manufacturing. They can accommodate various vaccine types, including multiepitope vaccines, protein subunits, virus-like particles (VLPs), and chimeric VLPs, ensuring a wide range of vaccine options.
Affordability and Safety: Plant-based vaccine production is cost-effective, scalable, and safe. Moreover, plants enable the synthesis of recombinant proteins post glycosylation, a capability lacking in E. coli-based systems.
Challenges to Plant-Based Vaccine Market Growth:
Efficiency Limitations: Plant-based platforms face efficiency challenges related to modifications, such as glycosylation, gene expression in prokaryotic chloroplasts, and limited trials using nuclear transformation.Development and Commercialization Gap: A knowledge gap exists between laboratory-based production and the commercialization of plant-based vaccines. This includes challenges in business planning, financing, and regulatory approval.
Country-Wise Insights:
- Booming U.S. Market: The United States witnesses seasonal variations in pathogenic diseases, leading to increased demand for novel plant-based vaccines. Growing R&D and product launches in the country are expected to drive market expansion.
- Lucrative German Market: Germany faces a high burden of viral diseases, including influenza. This high prevalence of influenza is expected to boost demand for plant-based vaccines.
- Emerging Japanese Market: Japan is on the brink of vaccine commercialization approvals. Clinical trials for plant-based COVID-19 vaccines have commenced, and upcoming approvals are expected to drive market growth.
Key Market Players:
Leading companies in the global plant-based vaccines market are focusing on next-generation plant-based expression technologies to expedite vaccine development and provide effective solutions against a range of illnesses.- Creative Biolabs
- Medicago Inc.
- iBio
- ICON
- EEA Consulting Engineers
- Kentucky BioProcessing, Inc.
- Baiya Phytopharm
- Protalix Biotherapeutics
Key Segments of Plant-Based Vaccines Industry Research
By Type:
- Viral Vaccines
- Bacterial Vaccines
- Others
By Application:
- Influenza
- Zika Virus
- Ebola Virus
- Others
By Source:
- Maize
- Tobacco
- Potatoes
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Market Overview
3. Global Plant-based Vaccines Market Outlook, 2018 - 2031
4. North America Plant-based Vaccines Market Outlook, 2018 - 2031
5. Europe Plant-based Vaccines Market Outlook, 2018 - 2031
6. Asia Pacific Plant-based Vaccines Market Outlook, 2018 - 2031
7. Latin America Plant-based Vaccines Market Outlook, 2018 - 2031
8. Middle East & Africa Plant-based Vaccines Market Outlook, 2018 - 2031
9. Competitive Landscape
10. Appendix
Companies Mentioned
- Creative Biolabs
- Medicago Inc.
- iBio
- ICON
- EEA Consulting Engineers
- Kentucky BioProcessing, Inc.
- Baiya Phytopharm
- Protalix Biotherapeutics
Methodology
LOADING...